骨质疏松-假性胶质瘤综合征(OPPG)患者对奈立膦酸治疗的临床与生化反应
本文报告一例因LRP5基因突变致骨质疏松-假性胶质瘤综合征(OPPG)的患者,经奈立膦酸治疗36个月后临床与生化反应令人鼓舞。作者认为双膦酸盐应在OPPG患者早期童年作为一线治疗。
要点
- OPPG为LRP5基因突变导致的罕见常染色体隐性综合征,表现为幼年起病的骨质疏松和眼部异常。
- 既往报道双膦酸盐(尤其是帕米膦酸和利塞膦酸)对该病有一定疗效。
- 本例患者经奈立膦酸治疗36个月后反应令人鼓舞。
核心结论
- 一例LRP5基因突变所致OPPG患者经36个月奈立膦酸治疗后显示令人鼓舞的反应。
- 作者认为双膦酸盐应在OPPG患者早期童年作为一线治疗。
研究设计与样本
- 病例报告:一例因LRP5基因突变致OPPG的患者接受奈立膦酸治疗并报告36个月疗程后的反应。
主要发现
- 该OPPG患者经36个月奈立膦酸治疗后的临床与生化反应令人鼓舞。
临床怎么用
- 作者认为双膦酸盐应在OPPG患者早期童年作为一线治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Osteoporosis-pseudoglioma syndrome (OPPG) is a rare autosomal recessive syndrome characterized by juvenile-onset osteoporosis and ocular abnormalities due to a low-density lipoprotein receptor-related protein 5 (LRP5) gene mutation. Treatment with bisphosphonates, particularly with pamidronate and risedronate, has been reported to be of some efficacy in this condition. We report on a patient with OPPG due to an LRP5 gene mutation, who showed an encouraging response after a 36-month period of neridronate therapy. We report a case of a patient treated with bisphosphonates. Bisphosphonates should be administered in OPPG patients as a first-line therapy during early childhood.
引用
- Celli M, D'Eufemia P, Persiani P, et al. Clinical and biochemical response to neridronate treatment in a patient with osteoporosis-pseudoglioma syndrome (OPPG). Osteoporos Int. 2017. PMID: 28866852. doi:10.1007/s00198-017-4214-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。